Search Beyond News…

Aurora Cannabis subsidiary secures EU‑GMP clearance, unlocking EU medical cannabis market access

Executive summary: Safari Flower Company received EU‑GMP certification at its Niagara facility. It enables Aurora Cannabis to export medical cannabis to EU markets under strict quality standards, opening a new revenue stream.

Who is involved: Safari Flower Company (subsidiary of Aurora Cannabis), Aurora Cannabis Inc., EU regulatory authorities.

Likely next: Aurora may begin shipping EU‑certified medical cannabis to European customers and pursue additional country‑specific authorizations.

On July 23, 2026, Safari Flower Company, a wholly owned subsidiary of Aurora Cannabis, announced that its Niagara facility has obtained EU‑Good Manufacturing Practice (GMP) certification. The certification allows the facility to produce medical cannabis products that meet the stringent quality standards required for sale in the European Union. This development removes a major regulatory barrier for Aurora’s international expansion and positions the company to supply EU‑regulated medical cannabis markets. Analysts note that the achievement could accelerate revenue growth from overseas medical cannabis sales.

Timeline

Analysis — what this means

Sectors affected

Regulatory implications

Sources

Related cases

Browse the full archive →